加味升降散对饮停胸胁型结核性胸膜炎患者胸腔积液ADA,外周血Treg细胞及DC细胞亚群的影响

高云; 王涛; 高月平; 张占英; 赵永辰

doi:10.13422/j.cnki.syfjx.2017120173

您当前的位置：

首页 >

文章列表页 >

加味升降散对饮停胸胁型结核性胸膜炎患者胸腔积液ADA,外周血Treg细胞及DC细胞亚群的影响

临床 | 更新时间：2024-01-04

- 加味升降散对饮停胸胁型结核性胸膜炎患者胸腔积液ADA,外周血Treg细胞及DC细胞亚群的影响
- Effect of Jiawei Shengjiangsan on Pleural Effusion ADA, Peripheral Blood Treg and DC Cell Subsets of Patients of Tuberculous Pleurisy with Fluid-retention in Chest and Hypochondrium
- 中国实验方剂学杂志 2017年23卷第12期页码：173-177
- 作者机构：
- 作者简介：
- 基金信息：
  
  保定市科技局立项课题项目（10ZF059）
- DOI：10.13422/j.cnki.syfjx.2017120173
  中图分类号： R259
- 纸质出版日期：2017
- 稿件说明：
移动端阅览
高云, 王涛, 高月平, 等. 加味升降散对饮停胸胁型结核性胸膜炎患者胸腔积液ADA,外周血Treg细胞及DC细胞亚群的影响[J]. 中国实验方剂学杂志, 2017,23(12):173-177.

GAO Yun, WANG Tao, GAO Yue-ping, et al. Effect of Jiawei Shengjiangsan on Pleural Effusion ADA, Peripheral Blood Treg and DC Cell Subsets of Patients of Tuberculous Pleurisy with Fluid-retention in Chest and Hypochondrium[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(12): 173-177.
高云, 王涛, 高月平, 等. 加味升降散对饮停胸胁型结核性胸膜炎患者胸腔积液ADA,外周血Treg细胞及DC细胞亚群的影响[J]. 中国实验方剂学杂志, 2017,23(12):173-177. DOI： 10.13422/j.cnki.syfjx.2017120173.

GAO Yun, WANG Tao, GAO Yue-ping, et al. Effect of Jiawei Shengjiangsan on Pleural Effusion ADA, Peripheral Blood Treg and DC Cell Subsets of Patients of Tuberculous Pleurisy with Fluid-retention in Chest and Hypochondrium[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(12): 173-177. DOI： 10.13422/j.cnki.syfjx.2017120173.

摘要

目的：探讨饮停胸胁型结核性胸膜炎（TBP）患者应用加味升降散对其胸腔积液腺苷脱氨酶（ADA）及外周血调节性T细胞（Treg）与树突状细胞（DC）细胞亚群的影响。方法：选取河北大学附属医院2014年1月-2015年9月收治的134例TBP患者，按照随机数字表法均分为两组。对照组予以胸腔穿刺抽液+抗结核药物的常规治疗；观察组在此基础上，给予加味升降散治疗。记录比较两组连续治疗2个月时临床疗效，胸腔积液ADA水平，外周血Treg与DC细胞亚群占外周血单个核细胞（PBMC）的百分比。结果：连续治疗2个月后，观察组总有效率（95.52%）高于对照组（83.58%）（P<0.05）。两组治疗2个月时胸腔积液ADA水平均显著低于治疗前（P<0.01）；与对照组同期比较，观察组治疗2个月时胸腔积液ADA水平显著降低（P<0.01）。与治疗前比较，两组患者治疗2个月时CD25+/PBMC，CD25+/CD4+及CD25+FoxP3+/CD25+均显著降低（P<0.01）；且观察组治疗2个月时外周血Treg细胞亚群改善程度较对照组同期降低显著（P<0.01）。两组治疗2个月时DC1/PBMC，DC2/PBMC及DC1/DC2均明显高于治疗前（P<0.05）；且与对照组同期比较，观察组治疗2个月时外周血DC细胞亚群改善幅度更为明显（P<0.05）。结论：TBP患者在常规西医治疗基础上应用加味升降散更能有效改善其临床症状，降低胸腔积液ADA水平，调节机体细胞免疫，疗效切实，为临床防治TBP提供了新思路。

Abstract

Objective: To study the effect of Jiawei Shengjiangsan on pleural effusion adenosine deaminase (ADA)

peripheral regulatory blood T cells (Treg) and dendritic cells (DC) cell subsets of patients with tuberculous pleurisy (TBP) with fluid-retention in chest and hypochondrium. Method: A total of 134 cases of TBP patients treated at our hospital from January 2014 to September 2015 TBP were selected and divided into two groups according to the random number table method. Control group was given the routine therapy of pleural effusion and anti-tuberculosis drugs. In addition to that

observation group was given Jiawei Shengjiangsan. Clinical efficacy

pleural effusion ADA levels and percentage ratio of peripheral blood Treg and DC cell subsets accounted for peripheral blood mononuclear cells (PBMC) of two groups after continuous treatment for 2 months were compared. Result: After continuous treatment for 2 months

the total effective rate of observation group was 95.52%

which was obviously higher than 83.58% in control group (P<0.05). The ADA levels of pleural effusion after treatment for 2 months in two groups were significantly lower than those before the treatment (P<0.01). Compared with that of control group

the ADA level of pleural effusion was significantly lower in observation group after treatment for 2 months (P<0.01). Compared with before the treatment

CD25+/PBMC

CD25+/CD4+ and CD25+FoxP3+/CD25+ of two groups after treatment for 2 months decreased significantly (P<0.01). And after treatment for 2 months

the improvement of peripheral blood Treg cell subsets in observation group was obviously lower than that of control group of the same time period (P<0.01). After treatment for 2 months

DC1/PBMC

DC2/PBMC and DC1/DC2 of two groups were significantly higher than before the treatment (P<0.05). And compared with that of control group

the improvement of the peripheral blood DC cell subsets in observation group after treatment for 2 months was more obvious (P<0.05). Conclusion: The application of Jiawei Shengjiangsan for TBP patients in addition to routine western medicine therapy can effectively improve the clinical symptoms

reduce the level of ADA in pleural effusion

and adjust cellular immunity

achieve an accurate effect

and provide new ideas for the prevention and treatment of TBP.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

加味升降散对饮停胸胁型结核性胸膜炎的疗效及对患者胸腔积液ADA,免疫功能,T淋巴细胞及炎症因子水平的影响